Use of Chemotherapy and Androgen Signaling–targeted Inhibitors in Patients with Metastatic Prostate Cancer

Ronald de Wit, B Tombal, S Freedland

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)

Abstract

The recent CARD study has shown that sequential use of androgen receptor (AR)-targeted therapies is associated with worse outcomes when compared with cabazitaxel chemotherapy. Here we argue that this accounts for the majority of patients previously treated with an AR-targeted agent.

Original languageEnglish
Pages (from-to)170-172
Number of pages3
JournalEuropean Urology
Volume79
Issue number2
DOIs
Publication statusPublished - Feb 2021

Research programs

  • EMC OR-01

Fingerprint

Dive into the research topics of 'Use of Chemotherapy and Androgen Signaling–targeted Inhibitors in Patients with Metastatic Prostate Cancer'. Together they form a unique fingerprint.

Cite this